Literature DB >> 2865080

Serologic and protective characterization of Moraxella bovis pili.

C Lehr, H G Jayappa, R A Goodnow.   

Abstract

This study was conducted to determine the protective nature of purified M. bovis EPP 63 pili in controlling experimentally induced Infectious Bovine Keratoconjunctivitis, and to determine antigenic similarity of pili isolated from various M. bovis isolates. Ten calves were vaccinated twice, 28 days apart, with 5.0 mg (protein) EPP 63 purified pili. Ten calves were maintained as non-vaccinated controls. All calves were exposed to ultraviolet light prior to challenge. The calves were challenged by instilling approximately 2.0 X 10(8) CFU of EPP 63 piliated organisms into the conjunctival sac. Antisera to respective pili types were prepared by immunizing the rabbits with purified pili from M. bovis strains EPP 63, FLA 64, IBH 68, MED 72 and ATCC 10900. Rabbit serum was evaluated for cross reactivity by enzyme-linked immunosorbent assay (ELISA). Purity of pili preparations was demonstrated on SDS-PAGE gels. Molecular weight of pili subunit was determined to be approximately 20,000 for EPP 63, 19,500 for IBH 68 and ATCC 10900, and 17,500 for FLA 64 and MED 72. One of 10 (10%) calves vaccinated with EPP 63 purified pili, and 6 of 10 (60%) nonvaccinated controls developed IBK, respectively. Average eye scores for vaccinates and controls were 0.05 and 0.85, respectively. Significant cross-reaction was found between EPP 63 and MED 72 pili. FLA 64 and ATCC 10900 were similar; however, antiserum to IBH 68 pili showed some degree of cross reaction with other pili.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865080

Source DB:  PubMed          Journal:  Cornell Vet        ISSN: 0010-8901


  11 in total

Review 1.  Pilins of Bacteroides nodosus: molecular basis of serotypic variation and relationships to other bacterial pilins.

Authors:  T C Elleman
Journal:  Microbiol Rev       Date:  1988-06

2.  Antigenic analysis of fimbrial proteins from Moraxella bovis.

Authors:  L J Moore; J M Rutter
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

3.  Ocular immune responses in steers following intranasal vaccination with recombinant Moraxella bovis cytotoxin adjuvanted with polyacrylic acid.

Authors:  John A Angelos; Judy M Edman; Munashe Chigerwe
Journal:  Clin Vaccine Immunol       Date:  2013-12-11

4.  Sequence analysis of the inversion region containing the pilin genes of Moraxella bovis.

Authors:  K A Fulks; C F Marrs; S P Stevens; M R Green
Journal:  J Bacteriol       Date:  1990-01       Impact factor: 3.490

5.  Western blot (immunoblot) analysis of the fimbrial antigens of Bacteroides nodosus.

Authors:  B J Anderson; J S Mattick; P T Cox; C L Kristo; J R Egerton
Journal:  J Bacteriol       Date:  1987-09       Impact factor: 3.490

6.  Characterization of the submerged growth of Moraxella bovis.

Authors:  M Mandl; V Simon; P Horavová; B Smíd; S Standara
Journal:  Folia Microbiol (Praha)       Date:  1987       Impact factor: 2.099

7.  Characterization of the pilin gene of Moraxella bovis Dalton 2d and expression of pili from M. bovis in Pseudomonas aeruginosa.

Authors:  T C Elleman; P A Hoyne; A W Lepper
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Antigenic relationships of Moraxella bovis isolates recovered from outbreaks of infectious bovine keratoconjunctivitis in Argentina, Brazil, and Uruguay between 1983 and 2000.

Authors:  Fabrício Rochedo Conceição; Fernando Paolicchi; Ana Lia Cobo; Carlos Gil-Turnes
Journal:  Can J Vet Res       Date:  2003-10       Impact factor: 1.310

9.  Expression of pili from Bacteroides nodosus in Pseudomonas aeruginosa.

Authors:  T C Elleman; P A Hoyne; D J Stewart; N M McKern; J E Peterson
Journal:  J Bacteriol       Date:  1986-11       Impact factor: 3.490

10.  Morphogenetic expression of Bacteroides nodosus fimbriae in Pseudomonas aeruginosa.

Authors:  J S Mattick; M M Bills; B J Anderson; B Dalrymple; M R Mott; J R Egerton
Journal:  J Bacteriol       Date:  1987-01       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.